Cargando…

Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model

Misfolded proteins in Alzheimer’s disease and Parkinson’s disease follow a well-defined connectomics-based spatial progression. Several anti-tau and anti-alpha synuclein (aSyn) antibodies have failed to provide clinical benefit in clinical trials despite substantial target engagement in the experime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geerts, Hugo, Bergeler, Silke, Walker, Mike, van der Graaf, Piet H., Courade, Jean-Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474108/ https://www.ncbi.nlm.nih.gov/pubmed/37658103 http://dx.doi.org/10.1038/s41598-023-41382-0

Ejemplares similares

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease
por: Geerts, Hugo, et al.
Publicado: (2023)

Alpha-synuclein and tau: teammates in neurodegeneration?
por: Moussaud, Simon, et al.
Publicado: (2014)

From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy
por: Colin, Morvane, et al.
Publicado: (2019)

Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau
por: Courade, Jean-Philippe, et al.
Publicado: (2018)

A modeling informed quantitative approach to salvage clinical trials interrupted due to COVID‐19
por: Geerts, Hugo, et al.
Publicado: (2020)

Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization
por: Dominguez-Meijide, Antonio, et al.
Publicado: (2020)

A Powerful Yeast Model to Investigate the Synergistic Interaction of α-Synuclein and Tau in Neurodegeneration
por: Ciaccioli, Gianmario, et al.
Publicado: (2013)

Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson’s Disease
por: Hu, Shanshan, et al.
Publicado: (2020)

Alpha Synuclein: Neurodegeneration and Inflammation
por: Forloni, Gianluigi
Publicado: (2023)

Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology
por: Betts, Alison, et al.
Publicado: (2020)

Interactions and Cytotoxicity of Human Neurodegeneration- Associated Proteins Tau and α-Synuclein in the Simple Model Dictyostelium discoideum
por: Mroczek, Katelyn, et al.
Publicado: (2021)

Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody
por: Albert, Marie, et al.
Publicado: (2019)

Neurodegeneration and the ordered assembly of α-synuclein
por: Spillantini, Maria Grazia, et al.
Publicado: (2017)

Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges
por: Geerts, Hugo, et al.
Publicado: (2019)

The role of tau in neurodegeneration
por: Gendron, Tania F, et al.
Publicado: (2009)

Binding Stability of Antibody—α-Synuclein Complexes Predicts the Protective Efficacy of Anti-α-synuclein Antibodies
por: Höllerhage, Matthias, et al.
Publicado: (2022)

β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population
por: Rosenberg, Anna, et al.
Publicado: (2022)

Interactions between Calcium and Alpha-Synuclein in Neurodegeneration
por: Rcom-H’cheo-Gauthier, Alex, et al.
Publicado: (2014)

Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story
por: Imbimbo, Bruno P., et al.
Publicado: (2022)

Tau and DNA Damage in Neurodegeneration
por: Colnaghi, Luca, et al.
Publicado: (2020)

Sleep spindles, tau, and neurodegeneration
por: Neylan, Thomas C, et al.
Publicado: (2022)

Tau as a Biomarker of Neurodegeneration
por: Holper, Sarah, et al.
Publicado: (2022)

Mechanism of Anti-α-Synuclein Immunotherapy
por: Lee, Jun Sung, et al.
Publicado: (2016)

α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration
por: Tran, Hien T., et al.
Publicado: (2014)

Anti-tau antibody reduces insoluble tau and decreases brain atrophy
por: Yanamandra, Kiran, et al.
Publicado: (2015)

Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson’s Disease
por: König, Annekatrin, et al.
Publicado: (2018)

Frequency‐Domain Response Analysis for Quantitative Systems Pharmacology Models
por: Schulthess, Pascal, et al.
Publicado: (2017)

Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration
por: Ghiglieri, Veronica, et al.
Publicado: (2018)

Targeted proteolytic products of τ and α-synuclein in neurodegeneration
por: Xia, Yuxing, et al.
Publicado: (2021)

Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of α-synuclein and Parkin levels in rotenone-induced Parkinson’s disease in rats
por: Ahmed, Sanaa, et al.
Publicado: (2022)

Anti-Apoptotic Effects of Carotenoids in Neurodegeneration
por: Park, Han-A, et al.
Publicado: (2020)

Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting
por: Blömeke, Lara, et al.
Publicado: (2022)

Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer’s Disease
por: Geerts, Hugo, et al.
Publicado: (2021)

Tau binding protein CAPON induces tau aggregation and neurodegeneration
por: Hashimoto, Shoko, et al.
Publicado: (2019)

Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody
por: Luo, Wenjie, et al.
Publicado: (2015)

F189. PERSONALIZED MEDICINE: ESTIMATING THE IMPACT OF GENOTYPES ON ANTIPSYCHOTIC EFFICACY USING A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH
por: Geerts, Hugo, et al.
Publicado: (2018)

Toward Predicting Impact of Common Genetic Variants on Schizophrenia Clinical Responses With Antipsychotics: A Quantitative System Pharmacology Study
por: Spiros, Athan, et al.
Publicado: (2021)

A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson’s Disease
por: Roberts, Patrick, et al.
Publicado: (2016)

A Review of Quantitative Systems Pharmacology Models of the Coagulation Cascade: Opportunities for Improved Usability
por: Chung, Douglas, et al.
Publicado: (2023)

Regulation of Pom cluster dynamics in Myxococcus xanthus
por: Bergeler, Silke, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h7u406o9gn3oj4ak2vk1varvuf